Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Alaunos Therapeutics, Inc. (TCRT)

AIM ImmunoTech Inc. and Alaunos Therapeutics, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Alaunos Therapeutics, Inc. are of similar size ($6.8M and $6.4M). Alaunos Therapeutics, Inc. grew revenue faster over the last twelve months: −17.7% against −21.5%. Alaunos Therapeutics, Inc. has the higher net margin (0.00% vs −15,021.1%) and the lower return on invested capital (−480.4% vs 0.00%). Across the 17 metrics below, Alaunos Therapeutics, Inc. leads on 9 and AIM ImmunoTech Inc. on 8.

Valuation

Metric AIM TCRT Biotechnology median
P/E n/m n/m 8.50
P/S 30.63 456.87 9.71
P/B 0.38 9.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.69 n/m 0.64
EV/Sales (69.58) 1,552.30 9.21
Earnings yield (1,718.41%) (72.62%) (33.15%)
Free cash flow yield (502.43%) (20.65%) (25.50%)

Profitability

Metric AIM TCRT Biotechnology median
Gross margin (23.16%) 100.00% 65.16%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) (185.95%) (56.36%)
Return on assets (169.28%) (128.30%) (48.04%)
Return on invested capital 0.00% (480.35%) 0.00%

Growth

Metric AIM TCRT Biotechnology median
Revenue growth (TTM) (21.49%) (17.65%) 6.02%
EPS growth (last fiscal year) 72.19% 24.66% 30.26%
Revenue growth, 5-year CAGR (11.60%) (49.08%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM TCRT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 0.77 4.72
Net debt to EBITDA 0.22 0.33 0.96

Dividend

Metric AIM TCRT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AIM TCRT Biotechnology median
Market cap 6.79m 6.38m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack